Immunotyping in tubo‐ovarian high‐grade serous carcinoma by PD‐L1 and CD8+ T‐lymphocytes predicts disease‐free survival

PD‐L1 immune checkpoint inhibitor expression was evaluated in high‐grade serous carcinoma (HGSC) ovary in the context of the overall immune landscape to determine its prognostic value. Consecutive cases of HGSC, 50 who underwent upfront surgery followed by adjuvant chemotherapy (HGSC‐U) and 50 who u...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2021-05, Vol.129 (5), p.254-264
Hauptverfasser:	Bansal, Akriti, Srinivasan, Radhika, Rohilla, Manish, Rai, Bhavana, Rajwanshi, Arvind, Suri, Vanita, Chandra Saha, Subhas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Ascitic fluid B7-H1 Antigen - metabolism Biomarkers, Tumor - metabolism CD4 antigen CD8 antigen CD8-Positive T-Lymphocytes - metabolism CD8-Positive T-Lymphocytes - pathology Chemotherapy Chemotherapy, Adjuvant Cystadenocarcinoma, Serous - drug therapy Cystadenocarcinoma, Serous - immunology Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - surgery Cytoreduction Surgical Procedures Disease-Free Survival Female High‐grade serous carcinoma Humans Immune checkpoint inhibitors Immunohistochemistry Immunophenotyping immunotyping Lymphocytes Lymphocytes, Tumor-Infiltrating - metabolism Lymphocytes, Tumor-Infiltrating - pathology Macrophages Medical prognosis Middle Aged Neoadjuvant Therapy Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery ovary PD-L1 protein PD‐L1 Prognosis Quality Surgery Survival T-Lymphocyte Subsets - metabolism T-Lymphocyte Subsets - pathology Tumor cells tumor microenvironment Tumor Microenvironment - immunology Tumor-Associated Macrophages - metabolism Tumor-Associated Macrophages - pathology Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!